XtalPi (2228.HK) was honored with the First Prize at the national finals of the 2025 “Data Element ×” Competition, held in Shanghai on November 25. The company was recognized for its project, “AI + Automation Technology Empowering Data Element Construction and Application in Drug R&D.”
The competition is a state-level showcase for data fusion and innovation, co-hosted by 20 key organizations including China’s National Data Administration, the Cyberspace Administration of China, and the Shanghai Municipal People’s Government.
Recognizing Innovation in Scientific AI
The 2025 “Data Element ×” Competition, running over seven months, attracted over 23,000 teams and 117,000 participants across 14 tracks. XtalPi’s project was one of only 17 to win the top national prize.
Notably, XtalPi was the sole First Prize winner in the newly established Open Innovation Track, a category designed to encourage original and disruptive new technologies, products, and models outside of the core industrial sectors.
Leveraging Data Elements for Drug Discovery
XtalPi’s award-winning project highlighted its approach to building a “data-driven, people-centric” research paradigm. The company utilizes a deep integration of quantum physics, AI, and robotic experimentation to generate high-quality vertical datasets through its AI-autonomous experimental platforms deployed across multiple locations.
- This process leverages over 200 proprietary high-precision physical and AI vertical models developed by XtalPi.
- The high-quality vertical data infrastructure, which includes various software and hardware platforms, is essential for accelerating high-value applications in drug R&D and new material discovery.
- A key component of this infrastructure is PatSight, a proprietary software for intelligent analysis of pharmaceutical patents. PatSight significantly enhances the efficiency of annotating medicinal patent data and has been made available to industry, academia, and research institutions in the biopharma sector.
Winning this prestigious national recognition reaffirms XtalPi’s pioneering role in the “AI for Science” domain and its commitment to applying data elements to create new quality productive forces in the global drug discovery landscape.
